Nuvation Bio Inc expected to post a loss of 17 cents a share - Earnings Preview

Nuvation Bio

05/08/2025 14:29

Nuvation Bio Inc NUVB.N, NUVB.K is expected to  show a fall in quarterly revenue when it reports  results on August 7 for the period ending June 30 2025

The San Francisco California-based  company is expected to report a 75.1% decrease in revenue to $357.14 thousand from $1.44 million a year ago, according to the mean estimate from 7 analysts, based on LSEG data.

​LSEG's mean analyst estimate for Nuvation Bio Inc is for a loss of 17 cents per share.

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 7 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."

The mean earnings estimate of analysts was unchanged in the last three months. ​

Wall Street's median 12-month price target for Nuvation Bio Inc is $6.00, about 61.5% above its last closing price of $2.31

Previous quarterly performance (using preferred earnings measure in US dollars). ​

QUARTER ENDING
STARMINESMARTESTIMATE®
LSEG IBES ESTIMATE
ACTUAL
BEAT, MET, MISSED
SURPRISE %
Mar. 31 2025
-0.16
-0.16
-0.16
Met
-1.1
Dec. 31 2025
-0.14
-0.14
-0.15
Missed
-8.7
Sep. 30 2024
-0.12
-0.13
-0.15
Missed
-15.4​
Jun. 30 2024
-0.06
-0.06
-0.15
Missed
-156.4
​​Mar. 31 2024
-0.09
-0.10
-0.07
Beat
26.9
Dec. 31 2023
-0.09
-0.10
-0.06
Beat
42.8​
Sep. 30 2023
-0.11
-0.11
-0.09
Beat
17.9
Jun. 30 2023
-0.11
-0.11
-0.09
Beat
19.5

This summary was machine generated August 5 at 13:29 GMT.  All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)